# Missouri Attorney General Targets Kratom Regulatory Challenges > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/kratom-regulatory-challenges-missouri-legal-action/ > **Published:** 2026-04-01T14:05:06-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T10:32:53-04:00 > **Clinical Summary:** Explore kratom regulatory challenges highlighted by Missouri attorney general's legal action against American Shaman's kratom and 7-OH products. --- ✦ New CED Clinical Relevance  #70Notable Clinical Interest  Emerging findings or policy developments worth monitoring closely. ⚒ Cannabis News  |  CED Clinic [Pain Management](https://cedclinic.com/cbd-cbg-topicals-for-eczema/)OpioidsRegulatoryDrug InteractionsAddiction Why This Matters This legal action highlights the regulatory gray zone surrounding kratom and synthetic mitragynine derivatives like 7-hydroxymitragynine, substances increasingly used by patients for pain and opioid withdrawal. Clinicians need to understand these products’ risks and their patients’ usage patterns, especially given their potential for dependence and drug interactions. Clinical Summary Missouri’s attorney general is pursuing legal action against American Shaman for selling kratom and 7-hydroxymitragynine (7-OH) products. Kratom contains mitragynine and 7-OH, compounds with opioid receptor activity that can provide analgesic and mood effects but also carry risks of dependence, withdrawal, and interactions with other medications. The synthetic 7-OH products may have enhanced potency compared to traditional kratom leaf preparations. These substances exist in a regulatory void, sold as supplements despite their pharmacologically active properties. Dr. Caplan’s Take “I regularly encounter patients using kratom, often without mentioning it initially because they don’t consider it ‘medicine.’ The synthetic derivatives like 7-OH represent a concerning escalation in potency that patients may not fully understand when purchasing these products.” Clinical Perspective 🧠 Ask patients directly about kratom use during medication reconciliation, as many don’t volunteer this information. Be aware that synthetic derivatives may have different risk profiles than traditional kratom preparations. Patients using these products for pain or mood should be counseled on potential interactions and withdrawal risks, particularly if they’re taking other CNS-active medications. 💬 Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/) Have thoughts on this? Share it: [𝕏 Share on X](https://twitter.com/intent/tweet?text=Just%20read%20this%20on%20CEDclinic.com%3A%20Missouri%20attorney%20general%20sues%20American%20Shaman%20to%20stop%20sale%20of%20kratom%2C%207-OH%20prod...%20%40drcaplan&url=https%3A//missouriindependent.com/2026/03/31/missouri-attorney-general-sues-american-shaman-to-stop-sale-of-kratom-7-oh-products/)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A//missouriindependent.com/2026/03/31/missouri-attorney-general-sues-american-shaman-to-stop-sale-of-kratom-7-oh-products/)[🦥 Share on BlueSky](https://bsky.app/intent/compose?text=Just%20read%20this%3A%20Missouri%20attorney%20general%20sues%20American%20Shaman%20to%20stop%20sale%20of%20kratom%2C%207-OH%20prod...%20--%20via%20%40drcaplan.bsky.social%20https%3A//missouriindependent.com/2026/03/31/missouri-attorney-general-sues-american-shaman-to-stop-sale-of-kratom-7-oh-products/)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan/)[📝 Read more on Substack](https://substack.com/@doctorapproved)[🔔 Subscribe via RSS](https://cedclinic.com/category/cannabis-news/feed/) 📰 Source: [https://missouriindependent.com/2026/03/31/missouri-attorney-general-sues-american-shaman-to-stop-sale-of-kratom-7-oh-products/](https://missouriindependent.com/2026/03/31/missouri-attorney-general-sues-american-shaman-to-stop-sale-of-kratom-7-oh-products/) Table of Contents - [FAQ](#FAQ)[What is the clinical relevance rating of this cannabis news?](#What_is_the_clinical_relevance_rating_of_this_cannabis_news) - [What medical areas does this cannabis research cover?](#What_medical_areas_does_this_cannabis_research_cover) - [Why is this cannabis news considered clinically significant?](#Why_is_this_cannabis_news_considered_clinically_significant) - [What should clinicians know about cannabis and opioid interactions?](#What_should_clinicians_know_about_cannabis_and_opioid_interactions) - [How does this relate to current pain management practices?](#How_does_this_relate_to_current_pain_management_practices) - [Related](#Related) ## FAQ #### What is the clinical relevance rating of this cannabis news? This article has been assigned CED Clinical Relevance #70, indicating “Notable Clinical Interest.” This means it contains emerging findings or policy developments that healthcare providers should monitor closely. #### What medical areas does this cannabis research cover? The research focuses on [pain management](https://cedclinic.com/cbd-cbg-topicals-for-eczema/) and opioid-related treatments. It also addresses regulatory considerations and potential drug interactions involving [cannabis therapeutics](https://cedclinic.com/firearms-regulatory-guidance-cannabis/). #### Why is this cannabis news considered clinically significant? The content represents emerging findings or policy developments in [cannabis medicine](https://cedclinic.com/essential-oils-industrial-hemp-antimicrobial-benefits/). Healthcare providers should pay attention to these developments as they may impact clinical practice and [patient care](https://cedclinic.com/cannabis-cardiovascular-risk-impact/) decisions. #### What should clinicians know about cannabis and opioid interactions? This research addresses important [drug interaction](https://cedclinic.com/glp-1-addiction-risk-reduction-benefits/) considerations between cannabis and opioids. Clinicians should be aware of potential therapeutic interactions and safety considerations when patients use both substances. #### How does this relate to current pain management practices? The findings provide insights into cannabis as a component of pain management strategies. This information may influence how healthcare providers approach multimodal pain treatment protocols and opioid alternatives. {“@context”: “https://schema.org”, “@type”: “NewsArticle”, “headline”: “Missouri attorney general sues American Shaman to stop sale of kratom, 7-OH products”, “url”: “https://missouriindependent.com/2026/03/31/missouri-attorney-general-sues-american-shaman-to-stop-sale-of-kratom-7-oh-products/”, “datePublished”: “2026-04-01T12:23:06Z”, “about”: “missouri attorney general sues american shaman”} [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) RELATED READING AT CED CLINIC Continue exploring the evidence [Missouri attorney general sues CBD American Shaman over kratom products – KY3](https://cedclinic.com/missouri-attorney-general-sues-american-shaman-kratom-products/) Detailed coverage of Missouri's legal action against American Shaman regarding kratom products. [Read More](https://cedclinic.com/missouri-attorney-general-sues-american-shaman-kratom-products/) [Missouri AG sues CBD American Shaman over kratom products – KFVS12](https://cedclinic.com/missouri-attorney-general-sues-cbd-american-shaman-kratom/) Insights into the Missouri attorney general's lawsuit targeting kratom sales by American Shaman. [Learn More](https://cedclinic.com/missouri-attorney-general-sues-cbd-american-shaman-kratom/) ['Gas station heroin' and other products parents should be aware of | Opinion](https://cedclinic.com/synthetic-cannabinoids-toxicology-gas-station-products-risks/) An opinion piece highlighting risks of synthetic substances including kratom derivatives. [Explore Article](https://cedclinic.com/synthetic-cannabinoids-toxicology-gas-station-products-risks/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).